OSCR stock forecast, quote, news & analysis
Oscar Health Inc is a healthcare technology company built around a full stack technology platform and a relentless focus on serving its members... Show more
Oscar Health (OSCR) Stock Analysis: Record Profitability and AI-Driven Expansion Reshape Investor Sentiment
Key Takeaways
- Oscar Health shares traded near $28.34 in late July 2026, retreating roughly 4.9% over the trailing 30 days after a powerful multi-month rally that saw the stock surge approximately 68% over the prior 90-day period.
- The company delivered record first-quarter 2026 earnings with net income of $679 million on $4.65 billion in revenue, representing a 53% year-over-year top-line increase and membership growth of 56% to 3.2 million.
- Operating leverage is accelerating as the medical loss ratio improved 490 basis points to 70.5% and the SG&A expense ratio fell to a historic low of 15.2%, driven by AI-powered efficiencies and disciplined cost management.
- Management reaffirmed full-year 2026 guidance targeting $18.7 billion to $19.0 billion in revenue and $250 million to $450 million in operating earnings, marking the anticipated return to sustained profitability.
- Strategic initiatives including the Lucie Health Marketplace launch, ICHRAx data exchange rollout, and co-founder Mario Schlosser's transition to an AI advisory role underscore the company's deepening commitment to technology-led healthcare disruption.
- Q2 2026 earnings scheduled for August 6 represent the next major catalyst, with analysts expecting the report to deliver further clarity on medical cost trends and risk adjustment normalization.
Current Market Snapshot
Oscar Health shares have experienced notable cooling in recent weeks following an extraordinary rally. After climbing roughly 68% over a 90-day stretch and reaching a 52-week high of $33.10, the stock has pulled back to approximately $28.34, a decline of about 4.9% over the past 30 days. This consolidation comes as investors digest the company's record first-quarter results and weigh the sustainability of margin improvements against broader market dynamics, including the expiration of enhanced premium tax credits and expected membership churn through 2026. With a market capitalization of roughly $9.7 billion, Oscar Health trades at a price-to-sales ratio of approximately 0.6x, well below the insurance industry average near 1.2x. The stock carries a consensus analyst rating of Hold, with price targets ranging widely — reflecting divergent views on whether the profitability inflection can be sustained. Institutional ownership stands at roughly 75.7%, though some funds trimmed positions in recent quarters while others, including D.E. Shaw and Jane Street, meaningfully increased their stakes.
Oscar Health (OSCR) Business Overview and Competitive Position
Oscar Health is a technology-first health insurance company built on a proprietary full-stack platform and a relentless focus on member experience. Founded in 2012 to capitalize on the Affordable Care Act marketplace, the company has grown to become the largest dedicated insurer in the individual market, serving approximately 3.2 million members across its Individual & Family plans as of Q1 2026. The company differentiates itself through a modern digital infrastructure that includes complimentary telehealth services, AI-powered member support tools like the Oswell health agent, and real-time pricing transparency features. Unlike legacy insurers burdened by outdated technology stacks, Oscar was built from the ground up with cloud-based software, enabling faster product innovation and lower administrative overhead. The company has expanded its footprint within its serviced regions from a 17% market share in 2025 to approximately 30% in 2026. Beyond its core insurance business, Oscar is broadening its addressable market through the newly launched Lucie Health Marketplace — a carrier-agnostic shopping platform — and ICHRA solutions that allow employers to offer defined-contribution health benefits. These adjacent ventures carry higher-margin profiles and require no risk-based capital, providing a complementary growth vector to the core insurance operations.
Recent Developments Driving OSCR
Several converging developments have shaped the narrative around Oscar Health in recent weeks. The standout event remains the company's Q1 2026 earnings report on May 6, which substantially exceeded expectations: earnings per share of $2.07 crushed the consensus estimate of $1.11, while the medical loss ratio of 70.5% reflected disciplined pricing and favorable prior-period reserve development of $68 million. Management also reaffirmed full-year guidance at the Goldman Sachs Global Healthcare Conference in June, pointing to favorable utilization trends and lighter-than-expected market morbidity. In a notable leadership move, co-founder Mario Schlosser transitioned from President of Technology and CTO to a Co-Founder & Advisor role focused on advancing artificial intelligence and digital health initiatives, effective June 1 — a shift that the market interpreted as signaling continuity rather than disruption. Analyst coverage remains mixed: Wells Fargo initiated at Equal Weight with a $20 target, while UBS maintained a Neutral rating and raised its target to $20. Wolfe Research began coverage with a Peer Perform designation. Meanwhile, FactSet consensus EPS estimates for 2026 were revised upward from $1.00 to $1.07, reflecting growing confidence in the earnings trajectory. On the insider activity front, CEO Mark Bertolini purchased one million shares at $11.92 in April, though other insiders — including director Mario Schlosser — sold significant blocks under pre-arranged 10b5-1 plans. The company also announced that its Q2 2026 results will be released before market open on August 6, with a conference call to follow.
Trending AI Robots
In an environment where AI-driven efficiency is a central theme for companies like Oscar Health, traders increasingly turn to automated tools to navigate fast-moving markets. Tickeron's Trending AI Robots page curates a selection of top-performing AI-powered trading bots from a universe of hundreds that collectively trade thousands of tickers. Only the most relevant and consistently high-performing bots appear in this curated section, giving users visibility into strategies spanning various timeframes, asset classes, and performance metrics. Whether focused on short-term swing trades, momentum signals, or longer-term thematic positioning, these bots offer a data-driven complement to traditional research. For traders seeking to augment their decision-making with real-time AI signals, the Trending AI Robots page provides a streamlined entry point into automated trading strategies.
2026 Outlook and What Investors Should Watch
The second half of 2026 presents several critical milestones for Oscar Health. The upcoming Q2 earnings report on August 6 will be closely scrutinized for medical cost trends as new members begin utilizing benefits and reaching annual deductibles, providing the first meaningful test of whether the favorable Q1 MLR of 70.5% can normalize toward the full-year guided range of 82.4% to 83.4%. Risk adjustment dynamics remain a key variable — Q1 ran at approximately 24% of direct premiums versus the expected full-year rate of 20%, and the resolution of this gap will influence reported revenue and margins through year-end. The company's Investor Day on September 16 is expected to deliver long-term strategic detail on the Lucie Health Marketplace and ICHRA growth trajectory, potentially serving as a valuation catalyst. Macro risks include the expiration of enhanced premium tax credits, which is expected to drive gradual membership churn toward pre-ARPA levels, and any shifts in ACA marketplace policy following federal or state regulatory changes. Competitive exits from the individual market by certain carriers could offset some of this churn by redirecting members toward Oscar's plans. On the cost side, AI-driven automation — including the Oswell health agent now handling 86% of member inquiries and agentic AI tools that reduced response times by 67% during peak enrollment — represents a structural efficiency lever that could further compress SG&A below the 15.2% achieved in Q1. Consensus estimates project full-year 2026 EPS of approximately $0.47 and 2027 EPS of $1.10, implying a sharp profitability ramp that will be tested as the year unfolds.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
OSCR's Indicator enters downward trend
The Aroon Indicator for OSCR entered a downward trend on July 31, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 280 similar instances where the Aroon Indicator formed such a pattern. In of the 280 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for OSCR moved out of overbought territory on July 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for OSCR turned negative on July 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OSCR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
OSCR broke above its upper Bollinger Band on July 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 30, 2026. You may want to consider a long position or call options on OSCR as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where OSCR advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OSCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.656) is normal, around the industry mean (4.044). P/E Ratio (34.550) is within average values for comparable stocks, (152.439). OSCR's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.248). OSCR's Dividend Yield (0.000) is considerably lower than the industry average of (0.019). P/S Ratio (0.643) is also within normal values, averaging (0.631).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OSCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ManagedHealthCare